Andrew D Fesnak, MD
Associate Professor of Clinical Pathology and Laboratory Medicine
Attending physician, Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania
Associate Director, ITMAT Education, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania
Deputy Director, Clinical Cell and Vaccine Production Facility, University of Pennsylvania
Director, Hematopoietic Stem Cell Laboratory, Hospital of the University of Pennsylvania
Vice Chair of Education, Department of Pathology and Laboratory Medicine
Department: Pathology and Laboratory Medicine
Contact information
3400 Spruce Street
3 Ravdin Building - R3067
Philadelphia, PA 19104
3 Ravdin Building - R3067
Philadelphia, PA 19104
Office: 215-662-3325
Publications
Education:
BA (Molecular Biology)
Princeton University, 2005.
MD (Medical Doctorate)
University of Medicine and Dentistry of New Jersey - Robert Wood Johnson School of Medicine, 2011.
MHI (Masters of Health Care Innovation)
University of Pennsylvania, 2019.
Permanent linkBA (Molecular Biology)
Princeton University, 2005.
MD (Medical Doctorate)
University of Medicine and Dentistry of New Jersey - Robert Wood Johnson School of Medicine, 2011.
MHI (Masters of Health Care Innovation)
University of Pennsylvania, 2019.
Selected Publications
Fesnak, A: T Cell and Related Immunotherapies. Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. Shaz BH, Hillyer CD, Schwartz J, Gil MR, Nov 2024.Fesnak, A: Gene Therapy. Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects. Shaz BH, Hillyer CD, Schwartz J, Gil MR (eds.). Nov 2024.
Mack EA, Dougher MC, Ginda AM, Cahill C, Murter M, Schell K, Tanhehco YC, Bhoj VG, Fesnak AD, Siegel DL, Kambayashi T, Aqui NA, O'Doherty U: Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis. Blood 143(11): 1049-1054, Mar 2024.
Wang K, Tseng CY, Li Z, White C, Wang B, Levine BL, Fesnak AD: A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy. Cytotherapy 25(12): 1370-1379, Dec 2023.
Plesa G, Brennan AL, Levine JR, Hasenmayer D, Buchholz K, Migliaccio T, Holland D, Colligon TA, Mackey S, Dai A, Petrella J, Ngo S, Fesnak A, Davis MM, Siegel D: Multiple Efficiencies Gained by Implementing a Significantly Shorter Manufacturing Schedule for Production of CAR T Cell Products. Cytotherapy. Elsevier, 25(6): S9, May 2023 Notes: 10.1016/S1465-3249(23)00139-1.
Mackey, S. Dai, A. Gong, N. McGettigan, B. Jefferson, P. Petrella, J. Gohil, M. Fesnak, A. Siegel, D. Davis, M. M. Plesa, G.: Developing and Optimizing Multicolor Flow Cytometry Methods for the Manufacturing and Release of 3-Day HuCART Products. Cytotherapy. Elsevier, 25(6): S189-S190, May 2023 Notes: 10.1016/S1465-3249(23)00500-5.
Fesnak AD, Raval JS: Adverse Events of Cellular and Biotherapies. AABB Technical Manual, 21st edition 2023.
Fesnak AD, Siegel DL: Chimeric antigen receptor T cells and other cellular immunotherapies. Rossi's Principles of Transfusion Medicine, Sixth Edition. Simon TL, Gehrie EA, McCullough J, Roback JD, Snyder EL (eds.). Jul 2022.
Guleria I, de Los Angeles Muñiz M, Wilgo M, Bapat A, Cui W, Hsu YS, Jeyaraman M, Muthu S, Rodriguez F, Fesnak A, Celluzzi C, Sesok-Pizzini D, Reich-Slotky R, Spitzer T.: How do I: Evaluate the safety and legitimacy of unproven cellular therapies? Transfusion 62(3): 518-532, Mar 2022.
Frey NV, Gill S, Hwang WT, Luger SM, Martin ME, McCurdy, SR, Loren AW, Pratz KW, Perl AE, Barber-Rotenberg J, Marshall A, Ruella M, Lacey SF, Fraietta J Fesnak A, O'brien M, Schanne T, Brogdon JL, Engels B, Levine BL, June CH, Porter DL, Hexner EO : CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL. Blood 138(Supplement 1): 469, Dec 2021.